NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia

By | April 28th, 2019|News, Nityr|

Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile

By | November 22nd, 2018|News, Nityr|

Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA

By | November 19th, 2018|News, Nityr|

Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.

By | November 12th, 2018|News, Nityr|

Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs

By | December 12th, 2017|News, Nityr|

Cycle Pharmaceuticals launches free trial of NITYR in the US and Partners with Cambrooke Therapeutics to Support HT-1 Patients’ dietary needs

By | November 10th, 2017|News, Nityr|

Cycle Pharmaceuticals Partners with Cardinal as the Logistic Provider for Nityr in U.S.

By | August 7th, 2017|News, Nityr|

Cycle Pharmaceuticals Partners with Diplomat to Dispense NityrTM in U.S.

By | August 3rd, 2017|News, Nityr|

Cycle Pharmaceuticals Receives FDA Approval of Nityr™ (nitisinone) Tablets for Treatment of HT-1

By | August 1st, 2017|News, Nityr|